person · Reporting owner
Dougherty Michael Philip
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| bioAffinity Technologies, Inc.BIAF · Entity 8368 | Chief Financial Officer | January 31, 2024 | February 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
bioAffinity Technologies, Inc.
Report date January 31, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 84,203 |
Reported balance
After 2024-01-31 transaction · row 1
1 source rowRow 1 · 2024-01-31 · Grant · Acquired 31,847 · Balance 84,203 F1: Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2024 Filed Feb 2, 2024 21:17 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 31,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-004757 · ownership.xml · nonDerivative · entry 1 Dougherty Michael Philip · CIK 0001977228 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,203 F1 · shares: Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024. Read SEC document |
| June 06, 2023 Filed Jul 6, 2023 20:15 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 52,356 | $1.91 | $99,999.96 |
DisclosureSEC source: 0001493152-23-023818 · ownership.xml · nonDerivative · entry 1 Dougherty Michael Philip · CIK 0001977228 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,356 F1 · acquired: Represents a grant from bioAffinity Technologies, Inc. (the "Company") to Mr. Dougherty of 52,356 shares of common stock, par value $0.007, pursuant to the terms of an employment offer letter dated April 11, 2023, which was approved by the Board of Directors of the Company on May 11, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.